Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q06643 (
non-Hodgkin's lymphoma
)
11,307
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The B- and T-lymphocyte distribution was studied in 45 patients with malignant lymphoproliferative diseases. Eight patients with untreated Hodgkin's disease had normal mean percentages of
complement receptor
lymphocyte (CRL) cells and T-cells; however, the mean absolute number of T-cells was decreased. T-lymphocytes were also decreased in 3 patients with Hodgkin's disease treated 7-24 months previously. The number of T-lymphocytes increased markedly in all patients after treatment. Lymphocyte surface markers in
non-Hodgkin's lymphoma
showed distinctive patterns. Patients with leukemic reticuloendotheliosis or "hairy cell leukemia" characteristically had low percentages of CRL but normal or increased percentages of surface immunoglobulin-positive lymphocytes. The mean percentage and number of T-lymphocytes in this group were normal. Eight patients with nodular lymphocytic lymphoma and 2 patients with nodular lymphocytic-histiocytic lymphoma had normal mean numbers of CRL but decreased numbers of T-lymphocytes. Of 6 patients with diffuse lymphocytic lymphoma, 4 had elevated percentages and numbers of CRL. Despite low percentages, normal numbers of T-lymphocytes were found in 3 of these patients.
...
PMID:Immunologic abnormalities in patients with malignant lymphoproliferative diseases. 32 4
The total lymphocyte, T, B, and null cell content of peripheral blood from 32 healthy individuals and 30 patients with
non-Hodgkin's lymphoma
was determined. The patients had a significant reduction of B cells (
complement receptor
and membrane immunoglobulin positive cells) and a significant reduction in T cells. Correlation of patients' characteristics with lymphocyte abnormalities demonstrated several findings. Patients with advanced disease (III and IV) had significantly lower total lymphocyte and T cells than patients with localized disease (I and II) or normal controls. Patients with hypogammaglobulinemia had lower total lymphocyte and T cells than patients with normal gamma globulin status or normal controls. Patients with diffuse histology and B symptoms had lower total lymphocyte and T cells than normal controls. Discriminant analysis of lymphocyte populations categorized patients by disease extent and gamma globulin status with 70 and 68% accuracy, respectively.
...
PMID:Correlation of prognostic factors and blood lymphocyte subtypes in non-Hodgkin's lymphoma. 615 65
Surface receptors specific for either the C4b (CR1) or C3d (CR2) component of complement were examined on the neoplastic cells from 30 cases of
non-Hodgkin's lymphoma
of B-cell origin and on cells derived from 9 normal lymphoid tissues. Lymphocyte suspensions from non-neoplastic peripheral blood, tonsils, and lymph node contained three categories of
complement receptor
lymphocytes (CRL): cells with receptors for both C4b and C3d (CR1+, CR2+); cells with receptors for C4b but not C3d (CR1+, CR2-), and cells with receptors for C3d but not C4b (CR1-, CR2+). The mean of the proportion of total CRL expressing receptors only of C3d (CR1-, CR2+) was 0.35 for non-neoplastic tissues and 0.28 for malignant lymphomas of follicular center cell (FCC) origin. However, the proportion of cells with this phenotype was significantly higher in well differentiated lymphocytic lymphomas (WDL) and chronic lymphocytic leukemia (CLL) (0.65) and in intermediately differentiated lymphocytic lymphomas (IDL) (0.59). Histologic compartmentalization of the CRL subtypes was observed in frozen sections of normal lymphoid tissue. CR1+ cells were present in lymphoid follicles interfollicular areas, and in splenic red pulp. CR2+ cells were confined to lymphoid follicles. These findings strongly suggest that
complement receptor
phenotypes may be useful markers of B-cell differentiation.
...
PMID:Distribution of complement receptor subtypes in non-Hodgkin's lymphomas of B-cell origin. 697 40